Goat polyclonal to IGFBP3
ab77635 is expected to recognize both reported isoforms (NP_001013416.1 and NP_000589.2).
Sheep, Human, Pig
Mouse, Rat, Horse, Cow, Dog
, from the internal region of human IGFBP3 (NP_001013416.1; NP_000589.2).
Human breast cancer lysate.
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.02% Sodium Azide
Constituents: 0.5% BSA, Tris saline, pH 7.3
Concentration information loading...
Immunogen affinity purified
ab77635 is purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunising peptide.
Immunizing Peptide (Blocking)
Abpromise guarantee covers the use of
in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Peptide ELISA: Use at an assay dependent dilution. Antibody detection limit dilution 1/64000.
WB: Use at a concentration of 0.02 - 0.06 µg/ml. Predicted molecular weight: 32 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
Expressed by most tissues. Present in plasma.
Contains 1 IGFBP N-terminal domain.
Contains 1 thyroglobulin type-1 domain.
IGFBP3 levels are higher during extrauterine life and peak during puberty.
The thyroglobulin type-1 domain mediates interaction with HN.
Phosphorylation sites are present in the extracelllular medium.
Information by UniProt
Acid stable subunit of the 140 K IGF complex antibody
Binding protein 29 antibody
Binding protein 53 antibody
Western blot - Anti-IGFBP3 antibody (ab77635)
All lanes :
Anti-IGFBP3 antibody (ab77635) at 0.02 µg/ml
Lane 1 :
human breast cancer lysate (in RIPA buffer)
Lane 2 :
human breast cancer lysate (in RIPA buffer) with immunizing peptide
Lysates/proteins at 35 µg per lane.
Predicted band size:
Observed band size:
28 kDa (
why is the actual band size different from the predicted?
Additional bands at:
50 kDa (possible non-specific binding)
The additional band of 50 kDa was consistently observed. However this band was not blocked by the immunizing peptide and it is therefore a non specific signal.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"